Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ: QNTM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.26 (-5.04% 1D, market cap $20.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, QNTM ranks #342 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNTM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TXMD (TherapeuticsMD Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -12.9%, cap $20.8M) and AYTU (Aytu BioPharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M). Among the 5-stock peer group, QNTM leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).
For Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #342 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0% FCF Margin ($564.3K FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While QNTM currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.08) and Max Pain ($2.37) forces dealer call-delta covering toward $13.04.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) dropped -5.04% to $2.26, trading at 2% of its 52-week range ($2.07 – $12.42). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
LOS ANGELES, CA - October 20, 2026 (NEWMEDIAWIRE) - Quantum BioPharma (NASDAQ: QNTM) was featured in a Men's Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formula
Thermo Fisher reports Q3 earnings Oct. 21, with analysts expecting $6.40 EPS and $11.93B revenue; analysts remain bullish, raising price targets.
Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma just began a phase 2 MS trial.
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and
New agreement moves innovative Lucid-MS treatment from planning into execution. Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune
Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapyTORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -
AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the la
The FDA IND approval marks a pivotal step for the company's lead compound, known as Lucid-MS. What sets Quantum BioPharma's proprietary treatment apart from most existing MS therapies is its mechanism. Lucid-MS previousl
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), today announced its licensee – Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind u
TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on QNTM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for QNTM. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) ranks #342 by composite RQD confidence (46/100, grade D) and #830 by equity capitalization ($20.2M). Within this direct 5-issuer industry benchmark cohort, QNTM leads on earnings valuation at N/A trailing P/E, while TXMD leads on capital efficiency and profitability with -12.9% ROIC and — gross margin. QNTM currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QNTM
ACTIVE
Quantum Biopharma Ltd. Class B Subordinate Voting Shares | D | 46/100 | — | — | — | -5.04% | $20.2M | Benchmark Subject |
| TXMD TherapeuticsMD Inc. | E | 34/100 | — | — | -12.9% | +0.56% | $20.8M | /txmd-vs-qntm → |
| AYTU Aytu BioPharma Inc. | E | 27/100 | — | 69.0% | -35.0% | +0.52% | $21.0M | /aytu-vs-qntm → |
| COCP Cocrystal Pharma Inc. | D- | 36/100 | — | — | -35.0% | +6.53% | $19.2M | /cocp-vs-qntm → |
| AKTX Akari Therapeutics plc ADS | D- | 37/100 | — | — | -35.0% | -4.85% | $18.8M | /aktx-vs-qntm → |
Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $20.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ: QNTM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.26 (-5.04% 1D, market cap $20.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, QNTM ranks #342 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QNTM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TXMD (TherapeuticsMD Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -12.9%, cap $20.8M) and AYTU (Aytu BioPharma Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M). Among the 5-stock peer group, QNTM leads on earnings multiple (N/A) while TXMD leads on capital efficiency (-12.9% ROIC).
For Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #342 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
QNTM last traded at $2.26 (-5.04% on volume of 57,400 shares), positioning the stock -26.62% below its 50-day simple moving average ($3.08) and -40.99% below its 200-day simple moving average ($3.83). Across its 52-week range of $2.07 to $12.42, QNTM sits at the 1.8% percentile with a 14-day RSI of 36.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.98 to $2.54).
Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $2.26 (-5.04% 1D, market capitalization $20.2M).
Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,.
Sector correlations and upstream or downstream dependencies cannot be assessed from the source data.
Real-time company headlines, analyst actions, and sector developments for Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM) • Click "Debate This Headline" to argue it in the Roar Pit below
LOS ANGELES, CA - October 20, 2026 (NEWMEDIAWIRE) - Quantum BioPharma (NASDAQ: QNTM) was featured in a Men's Fitness article by Lakshan Weeraratne examining clinical trial results for Unbuzzd, an alcohol recovery formula
Thermo Fisher reports Q3 earnings Oct. 21, with analysts expecting $6.40 EPS and $11.93B revenue; analysts remain bullish, raising price targets.
Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma just began a phase 2 MS trial.
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and
New agreement moves innovative Lucid-MS treatment from planning into execution. Proprietary platform is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune
Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapyTORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -
AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the la
The FDA IND approval marks a pivotal step for the company's lead compound, known as Lucid-MS. What sets Quantum BioPharma's proprietary treatment apart from most existing MS therapies is its mechanism. Lucid-MS previousl
Here is why I am bullish on QNTM here at $2.38: Forensic balance-sheet pillar is the strongest component at 13 / 20, with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5.. Compare QNTM's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.26 are getting bought.
Both sides have a point here — QNTM's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
I respect the product at Quantum Biopharma Ltd. Class B Subordinate Voting Shares, but the stock at $2.38 is a different story. Whale 13F flow scores 3 / 20 and the Fundamental Cash Engine shows ROIC 0% and FCF yield 0%, pointing to weak institutional support and no measurable cash return.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: